Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-12-26
2006-12-26
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S134100, C424S138100, C424S009340
Reexamination Certificate
active
07153506
ABSTRACT:
The invention concerns the use, in the preparation of a medicine for treating cancer whereof the cells exhibit overexpression of a product of a gene of the myc-related family, of an anti-ferritin monoclonal antibody or a fragment thereof, said antibody or said fragment identifying an epitope common to acidic and basic human ferritins.
REFERENCES:
patent: 5156840 (1992-10-01), Goers et al.
patent: 5538726 (1996-07-01), Order
patent: 5843440 (1998-12-01), Pouletty et al.
“Isotopes” downloaded from the url . . . www.fact-index.com on Nov. 2, 2004.
Vriesendorp et al., (Journal of Clinical Oncology, vol. 9, pp. 918-928).
Houghton et al., (Jul. 1983, J. Exp. Med., vol. 158, pp. 53-65).
Ono et al., “Common epitopes in human isoferritins characterized by murine monoclonal antibodies,”J. Biochem., 99: 269-279 (1986).
Hahn et al., “Basic and acidic isoferritins in the sera of patients with neuroblastoma,”Cancer, 62: 1179-1182 (1988).
Kadouche et al., “Analysis of varios isoferritins with monoclonal antibodies,”Iron Building Proteins, 295: 187-190 (1982).
Boerner, P. et al., “Production of Antigen-Specific Human Monoclonal Antibodies From in Vitro-Primed Human Splenocytes”,The Journal of Immunology, 147:86-95 (1991).
Brams, P. et al., “Antigen-Specific IgG Responses from Naïve Human Splenocytes: In Vitro Priming Followed by Antigen Boost in the Scid Mouse”,The Journal of Immunology, 160:2051-2058 (1998).
Order, St. et al., “A New Method for Delivering Radioactive Cytotoxic Agents in Solid Cancers”,Int. J. Radiation Oncology Biol. Phys., 30(3):715-720 (1994).
“Serine Esterase: Enzyme which catalyzes the hydrolysis of esters and is characterized by a catalytically active serine residue in its active site”, Search of Swiss Prot database using keyword: Serine Esterase, http://www.expasy.org/cgi-bin/get-entries?KW=Serine%20esterase and http://www.ca.expasy.org/cgi-bin/sprot-search-de?serine%20esterase, search printed after Mar. 29, 2005.
“Serine Protease: Proteases, proteinases or peptidases describe the same group of enzymes that catalyse the hydrolysis of covalent peptidic bonds. In the case of serine proteases the mechanism (from Mellon College of Science Courses) is based on nucleophilic attack of the targeted peptidic bond by a serine”, http:www.biochem.wustl.edu/˜protease/ser—pro—overview.html and http://www.biochem.wustl.edu/˜protease/ser—pro—seq—list.html, printed Apr. 4, 2005.
Jeanteur, P., c-Myce an iron oncogene,Bulletin du Cancer, 86:250 (1999) (english translation).
Friguet et al., “Measurements of the True Affinity Constant in Solution of Antigen-Antibody Complexes by Enzyme-Linked Immunosorbent Assay”,Journal of Immunological Methods, 77 (1985) 305-319.
Kadouche Jean
Levy Rafael
Merchant & Gould P.C.
Monoclonal Antibodies Therapeutics “M.A.T.”
Yu Misook
LandOfFree
Use of anti-ferritin monoclonal antibodies in the treatment... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of anti-ferritin monoclonal antibodies in the treatment..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of anti-ferritin monoclonal antibodies in the treatment... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711564